Mcrae Capital Management Inc. lowered its position in Merck & Co., Inc. (NYSE:MRK – Free Report) by 1.4% during the second quarter, HoldingsChannel.com reports. The firm owned 9,069 shares of the company’s stock after selling 126 shares during the quarter. Mcrae Capital Management Inc.’s holdings in Merck & Co., Inc. were worth $1,123,000 as of its most recent SEC filing.
Several other hedge funds also recently bought and sold shares of the company. Vermillion & White Wealth Management Group LLC acquired a new position in Merck & Co., Inc. in the fourth quarter worth approximately $27,000. Bare Financial Services Inc bought a new stake in Merck & Co., Inc. in the fourth quarter worth approximately $28,000. Burkett Financial Services LLC acquired a new position in shares of Merck & Co., Inc. during the 4th quarter worth $28,000. Tidemark LLC bought a new position in shares of Merck & Co., Inc. during the 4th quarter valued at $31,000. Finally, Clear Investment Research LLC acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at $39,000. 76.07% of the stock is owned by institutional investors and hedge funds.
Merck & Co., Inc. Stock Performance
Shares of Merck & Co., Inc. stock traded up $0.05 during midday trading on Friday, hitting $116.60. The company had a trading volume of 8,360,045 shares, compared to its average volume of 8,672,231. Merck & Co., Inc. has a 1-year low of $99.14 and a 1-year high of $134.63. The business’s 50 day simple moving average is $122.36 and its two-hundred day simple moving average is $125.72. The stock has a market cap of $295.33 billion, a PE ratio of 129.56, a P/E/G ratio of 1.57 and a beta of 0.38. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.25 and a quick ratio of 0.99.
Merck & Co., Inc. Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Monday, October 7th. Investors of record on Monday, September 16th will be given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 2.64%. The ex-dividend date of this dividend is Monday, September 16th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 342.22%.
Wall Street Analysts Forecast Growth
MRK has been the topic of several analyst reports. Wolfe Research raised shares of Merck & Co., Inc. to a “strong-buy” rating in a research report on Wednesday, July 31st. Argus raised Merck & Co., Inc. to a “strong-buy” rating in a report on Wednesday, June 5th. Morgan Stanley boosted their target price on Merck & Co., Inc. from $132.00 to $134.00 and gave the stock an “equal weight” rating in a report on Thursday, July 11th. UBS Group decreased their target price on Merck & Co., Inc. from $148.00 to $142.00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. Finally, Truist Financial lifted their price target on shares of Merck & Co., Inc. from $142.00 to $143.00 and gave the company a “buy” rating in a research report on Friday, April 26th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, nine have given a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat.com, Merck & Co., Inc. has a consensus rating of “Buy” and a consensus price target of $134.58.
View Our Latest Research Report on MRK
Merck & Co., Inc. Company Profile
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
See Also
- Five stocks we like better than Merck & Co., Inc.
- How to Use Stock Screeners to Find Stocks
- Lumen: Among Top Performers Last Month, Still Has Warning Signs
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Baidu’s Strong Quarter Proves a Smart Pick for Michael Burry
- What is the Hang Seng index?
- Intuit Beats Q4 Earnings: AI, Dividends, and a Growth Strategy
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.